Potential plasma biomarkers of bladder cancer identified by proteomic analysis: A pilot study

Anna Lemańska-Perek*1,A–D,F, Jolanta Lis-Kuberka*1,A–D,F, Adam Lepczyński2,B,C,E,F, Alicja Dratwa-Chałupełnik2,B,C,E,F, Krzysztof Tupikowski1,A–E,F, Iwona Kątnik-Prastowska1,C,E,F, Małgorzata Ożgo1,B,C,E,F

1 Department of Chemistry and Immunochemistry, Wroclaw Medical University, Poland
2 Department of Physiology, Cytobiology and Proteomics, West Pomeranian University of Technology, Szczecin, Poland
3 Department of Urology and Oncologic Urology, Wroclaw Medical University, Poland
4 Department of Oncologic Urology, Lower Silesian Oncology Center, Wroclaw, Poland

A – research concept and design; B – collection and/or assembly of data; C – data analysis and interpretation; D – writing the article; E – critical revision of the article; F – final approval of the article

Abstract

Background. Bladder cancer diagnosis and surveillance includes cystoscopy and cytology. New methods for the detection of bladder cancer are needed, because cystoscopy is invasive and expensive, and because urine cytology is not sensitive enough.

Objectives. The aim of the study was to select potential plasma protein markers for bladder cancer which could be useful in developing a specific laboratory test to improve diagnosis and to establish treatment strategies in order to prevent the recurrence of the disease.

Material and methods. Plasma proteome maps were prepared based on 2-dimensional sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), combined with image gel analysis and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry of plasma samples from patients with urothelial bladder cancer, and they were compared to normal samples.

Results. The analyses of bladder cancer plasma samples allowed us to distinguish 3 groups of proteins whose relative abundance differed from that in normal samples. The 1st one comprised modified forms of plasma transferrin, fibrinogen gamma and complement C3b, which were absent in normal plasma. The 2nd group comprised haptoglobin, alpha-2-macroglobulin, vitamin D-binding protein, and pigment epithelium-derived factor, which occurred in the cancerous samples in large quantities. The 3rd group consisted of 3 molecular forms of immunoglobulin M (IgM), the relative abundance of which was significantly lower in the cancerous plasma samples.

Conclusions. The data indicated potential plasma biomarkers associated with inflammation, immunity and coagulation processes accompanying bladder cancer. They could be used for the development of a laboratory test(s) useful in clinical practice.

Key words: bladder cancer, biomarkers, proteomics, blood plasma glycoproteins, 2-dimensional gel electrophoresis
Introduction

Bladder cancer is often symptomless or may produce symptoms similar to a urinary tract infection. The tumors are routinely evaluated by cystoscopy, an invasive endoscopic procedure in order to aid diagnosis and post-treatment surveillance; intensive efforts have been undertaken to research and develop specific, sensitive and non-invasive tests based on a marker or group of markers. The aim is the early detection of primary or recurrent bladder cancer, which might help in establishing new treatment strategies, monitoring treatment and preventing recurrence.

Biomarkers described to date are tumor-associated molecules that degrade the components of the extracellular matrix and the urothelium. The US Food and Drug Administration has approved only a few of them, i.e., bladder tumor antigen (BTA), nuclear matrix protein 22 (NMP22) and fibrinogen degradation products. Moreover, the following molecules that are still under investigation have been reported to be associated with urinary carcinogenesis: BLCA-4, cytokeratin, fibronectin degradation products, uroplakin and their glycovariants, psoriasin, zinc-alpha-2-glycoprotein, pro-matrix metalloproteinase-2 (proMMP-2), matrix metalloproteinase-7 (MMP-7), and endostatin.

It has also been reported that the serum levels of CYFRA 21-1, protein, pro-matrix metalloproteinase-2 (proMMP-2), and fibrinogen degradation products.

Antigen (BTA), nuclear matrix protein 22 (NMP22) and fibrinogen degradation products.

In the opinion of Goodison et al., most of these biomarkers may be more useful as prognostic factors aiding therapeutic decisions. So far, none of the recommended urinary cancer biomarkers has been found to be sufficiently sensitive and specific to detect the entire spectrum of bladder cancers and to be used in routine clinical practice.

A new powerful and complex tool – proteomics, using 2-dimensional gel electrophoresis (2DE) to separate complete proteins in a sample, and mass spectrometry (MS) techniques, integrated with advanced computer software, make it possible to precisely identify, characterize and quantify the data. It is usually used to select potential marker proteins from complex protein mixtures for further analysis in larger groups. So far, a 2-dimensional gel-based proteomic approach coupled with MS and database searching has been used in order to explore the biomarkers of bladder cancer in urinary samples, tissue samples derived from biopsies from the transurethral resections of the bladder and patients’ plasma samples. Despite the abovementioned pioneering studies which have shed some light on the molecular mechanisms of bladder transitional cell carcinoma, there is still a great need to identify novel proteins or a group of bladder cancer biomarkers.

The aim of our study was to analyze differentially expressed levels of proteins in the plasma samples of patients with urothelial bladder cancer and acute cystitis by 2-dimensional sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), combined with image gel analysis and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) MS. Furthermore, the goal was to select a group of potential protein markers of bladder cancer which might be used in the development of a laboratory test(s) useful in clinical practice.

Material and methods

Blood plasma sample collection

Blood samples were obtained from 6 patients (54–91 years old) from the Department of Urology and Oncologic Urology of Wroclaw Medical University, Poland, who were being treated for bladder cancer. They were included in the study after providing written informed consent. The study was approved by the local Bioethical Committee (KB-406/2014).

The tumor was staged according to the TNM Classification of Malignant Tumors (TNM) and graded according to World Health Organization/International Society of Urologic Pathology (WHO/ISUP) 2004 criteria. The bladder cancer patients’ samples were divided into 2 groups according to the disease stage. The 1st group (C) comprised samples derived from 4 patients (2 women and 2 men, aged 70.8 ±17 years) with bladder tumors. The 2nd group (S), suspected of having cancer, consisted of 2 samples of patients (2 men, aged 62.5 ±0.7 years) who had undergone the transurethral resection of urothelial bladder cancer about 2 years earlier and were recurrence-free, but suffered from acute cystitis, lasting approx. 2 weeks.

The normal group (H) consisted of healthy volunteers aged 48.7 ±4 years (3 women).

Blood plasma sample preparation

The blood was drawn into plastic test tubes containing sodium citrate as an anticoagulant (1 part of 3.8% (w/v) citrate to 9 parts of the sample) and the plasma was separated from the blood cells by centrifugation at 2,000 × g for 15 min. The samples were stored at −76°C until used.

Blood plasma samples were depleted of the 2 most abundant proteins, using a ProteoExtract Albumin/IgG Removal Kit, Maxi (Calbiochem Merck, Geneva, Switzerland) to enrich the content of medium- and low-abundant protein in this medium. Depleted samples were subsequently precipitated with 4 volumes of cold acetone (−20°C) for 2 h and then centrifuged (20,800 × g, 4°C, 30 min) to obtain protein pellets. The protein pellets were dissolved in lysis buffer, containing 7 M of urea, 2 M of thiourea, 4% w/v of 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS), 1% w/v of DL-dithiothreitol (DTT), 0.2% w/v of 3–10 carrier ampholytes, and 2 mM of tributylphosphine (TBP). The protein concentration in the samples was determined by a modified Bradford assay (Bio-Rad6 Protein Assay; Bio-Rad, Hercules, USA), according to the manufacturer’s instructions.
Two-dimensional electrophoresis

Isoelectric focusing (IEF) was performed after loading blood plasma proteins (800 µg) on 5–8 cm nonlinear (NL) ReadyStrip IPG Strips (Bio-Rad). The proteins were separated for a total of 90,000 Vh, using a Protean IEF Cell (Bio-Rad). After IEF, the immobilized pH gradient (IPG) strips gained equilibrium at room temperature in a buffer solution containing 6 M of urea, 0.5 M of Tris/hydrochloric acid (pH 6.8), 2% w/v of sodium dodecyl sulfate (SDS), 30% w/v of glycerol, and additional 1% w/v of DTT to reduce the separated polypeptides (15 min) or 2.5% w/v of iodoacetamide to alkylate the proteins (20 min). Subsequently, the proteins were separated according to molecular range (SDS-PAGE) in 12% polyacrylamide gels (20 × 25 cm) at 40 V for 2.5 h, and then at 100 V for 16 h at 10°C, using a Protean Plus Dodeca Cell electrophoretic chamber (Bio-Rad). The proteins were visualized using Coomassie brilliant blue G-250 according to the protocol described by Lepczyński et al.21

Image analysis

The acquisition of gel images was performed using a GS-800 Calibrated Densitometer (Bio-Rad). To align and quantify the protein spots, the PDQuest Advanced 2D-Gel Analysis Software v. 8.0.1 (Bio-Rad) was used. PDQuest enables the user to calculate the value of relative protein expression based on several measurements of the optical density of spot coloration intensity, and to quantify the protein spot area in order to represent it as a dimensionless quantity. The normalization of the experimental data was performed using a local regression model (LOESS). The significance of the differences in protein spot abundances was confirmed using Student’s t-test within the PDQuest software. The significance of the differences was set at p ≤ 0.05. To evaluate the intragroup variability, the coefficients of variation (CV) for each group were calculated based on the information about the location and relative expression for each protein spot within the groups. The experimental molecular masses of the identified protein spots were computed using Precision Plus Protein Kaleidoscope Standard for SDS-PAGE (Bio-Rad) as the reference.

Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry protein identification

Following 2DE, the protein spots that showed significantly differentiated expression were identified by MALDI-TOF MS as previously described by Ożgo et al.22 Briefly, the protein spots were excised from the gels, deolorized (washed in a buffer solution containing 25 mM of ammonium bicarbonate [NH₄HCO₃] in 5% v/v of acetonitrile [ACN]), then washed twice in a solution of 25 mM of NH₄HCO₃ in 50% v/v of ACN, dehydrated (100% ACN), vacuum-dried, and incubated overnight with trypsin (8 µL/spot of 12.5 µg of trypsin/mL in 40 mM of NH₄HCO₃) (Promega, Madison, USA) at 37°C. After extraction with 100% ACN, combined with an equal volume of matrix solution (2.5 mg/mL of α-cyano-4-hydroxycinnamic acid [CHCA], 0.1% v/v of trifluoroacetic acid [TFA], 50% v/v of ACN), the obtained peptides were loaded onto a MALDI-MSP AnchorChip 600/96 plate (Bruker Daltonics, Bremen, Germany). Peptide Mass Standard II with a mass range of 700–3200 Da (Bruker Daltonics) was used to calibrate the mass scale.

The protein identification was done in the positive-ion reflector mode of a Microflex MALDI-TOF MS (Bruker Daltonics). The peptide mass fingerprinting (PMF) data were compared with the SwissProt/NCBI databases. The parameters used for the database search were: monoisotopic mass, 150 ppm mass accuracy, trypsin as an enzyme with 1 missed cleavage allowed, carbamidomethylation of cysteine as a fixed modification, and methionine oxidation as a variable modification. The results were further validated by the Mascot score and sequence coverage.

Heat map generation

PermutMatrix software v. 1.9.3 (The free access to the software is available on-line http://www.atgc-montpellier.fr/permutmatrix/) was used to create a heat map based on the data of the expression of the proteins in the healthy individuals, and in the cancer-suspected and cancerous patients.23 The data on protein expression level for each spot was normalized within rows, i.e., the mean expression level for each sample gel was calculated for each statistically differentially altered protein spot and the expression level of this protein for each gel was divided by the arithmetic mean. After division, it was subjected to base 2 logarithmic transformation. Thus, a negative value of the logarithm indicated a decrease in the expression, whereas a positive value showed an increase. In addition, the mean values were calculated based on the resulting values, but when the spot was absent on the gel (0 abundance), the 0 value was substituted by 1.

Results

Analysis of plasma proteome differences

The analysis revealed from 361 to 387 protein spots per analyzed 2D gel, representing the protein profiles of the human plasma. Of them, 327 spots matched to each analyzed gel were subjected to statistical analysis between the cancer groups C and S, and group H. The CV was estimated to be 51.5%, 46.6% and 53.3% for groups H, C and S, respectively.

The significant quantitative differences in protein profiles revealed 15 differentially expressed protein spots (Fig. 1) in the plasma samples of patients with urothelial
**Table 1.** Characterization of the plasma protein spots revealed by proteomic analyses of the bladder cancer plasma samples

<table>
<thead>
<tr>
<th>No.</th>
<th>Database protein name/identified blood plasma protein</th>
<th>Accession No.</th>
<th>Calculated Mr [kDa]</th>
<th>Theoretical pI/Mr [kDa]</th>
<th>Mean relative abundance in the groups</th>
<th>MALDI-TOF MS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>H</td>
<td>C</td>
</tr>
<tr>
<td>1</td>
<td>haptoglobin/haptoglobin β chain</td>
<td>Q9UC67</td>
<td>43.1</td>
<td>6.13/45.86</td>
<td>29,968.2</td>
<td>78,764.0</td>
</tr>
<tr>
<td>2</td>
<td>haptoglobin/haptoglobin β chain</td>
<td>Q9UC67</td>
<td>42.9</td>
<td>6.13/45.86</td>
<td>2,616.9</td>
<td>12,149.3</td>
</tr>
<tr>
<td>3</td>
<td>vitamin D-binding protein</td>
<td>P02774</td>
<td>59.2</td>
<td>5.40/54.53</td>
<td>5,771.8</td>
<td>47,832.1</td>
</tr>
<tr>
<td>4</td>
<td>alpha-2-macro globulin</td>
<td>1009174A</td>
<td>201.6</td>
<td>5.95/162.07</td>
<td>234.8</td>
<td>731.1</td>
</tr>
<tr>
<td>5</td>
<td>fibrinogen gamma</td>
<td>0602239A</td>
<td>54.8</td>
<td>5.54/46.82</td>
<td>4,206.8</td>
<td>8,799.9</td>
</tr>
<tr>
<td>6</td>
<td>fibrinogen gamma</td>
<td>0602239A</td>
<td>54.1</td>
<td>5.54/46.82</td>
<td>137,003.0</td>
<td>246,012.8</td>
</tr>
<tr>
<td>7</td>
<td>fibrinogen gamma</td>
<td>0602239A</td>
<td>51.7</td>
<td>5.54/46.82</td>
<td>N/D</td>
<td>2,274.0</td>
</tr>
<tr>
<td>8</td>
<td>serotransferrin</td>
<td>P02787</td>
<td>54.9</td>
<td>6.81/79.29</td>
<td>N/D</td>
<td>1,626.1</td>
</tr>
<tr>
<td>9</td>
<td>human complement component C3b, chain B</td>
<td>2I07_B</td>
<td>125.4</td>
<td>5.16/104.91</td>
<td>N/D</td>
<td>645.7</td>
</tr>
<tr>
<td>10</td>
<td>human complement component C3b, chain B</td>
<td>2I07_B</td>
<td>80.0</td>
<td>5.16/104.91</td>
<td>3,139.7</td>
<td>7,066.4</td>
</tr>
<tr>
<td>11</td>
<td>pigment epithelium-derived factor</td>
<td>AAA84914</td>
<td>51.0</td>
<td>6.56/40.22</td>
<td>1,270.5</td>
<td>2,831.3</td>
</tr>
<tr>
<td>12</td>
<td>insulin-like growth factor binding protein, acid labile subunit</td>
<td>AAH25681</td>
<td>89.3</td>
<td>6.33/66.77</td>
<td>1,367.2</td>
<td>870.4</td>
</tr>
<tr>
<td>13</td>
<td>Ig mu chain C region/lgM heavy chain</td>
<td>P01871</td>
<td>83.7</td>
<td>6.35/49.96</td>
<td>15,616.3</td>
<td>3,876.4</td>
</tr>
<tr>
<td>14</td>
<td>Ig mu chain C region/lgM heavy chain</td>
<td>P01871</td>
<td>83.0</td>
<td>6.35/49.96</td>
<td>35,847.6</td>
<td>7,263.2</td>
</tr>
<tr>
<td>15</td>
<td>Ig mu chain C region/lgM heavy chain</td>
<td>P01871</td>
<td>82.6</td>
<td>6.35/49.96</td>
<td>51,699.2</td>
<td>16,930.2</td>
</tr>
</tbody>
</table>

Table 1 lists the differentially expressed plasma proteins abundantly occurring in the plasma samples of patients with bladder cancer and of healthy controls. The proteins were revealed (see labeled spots in Fig. 1) and identified by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF/TOF MS), following 2-dimensional electrophoresis (2DE) analysis. Protein names and accession numbers are given as found in the SwissProt/NCBI databases. C – patients with bladder tumors; H – healthy controls; IgM – immunoglobulin M; Mr – molecular mass; N/D – not detected in the normal plasma samples; pI – isoelectric point; S – patients suspected of having cancer.

bladder cancer and acute cystitis spots. The matched protein names identified by SwissProt/NCBI databases are given in Table 1. Fifteen selected spots were identified as 9 proteins (Table 1). They include the following proteins: 2 molecular forms of haptoglobin β chain (spot 1: 43.1 kDa and spot 2: 42.9 kDa), vitamin D-binding protein (spot 3: 59.2 kDa), alpha-2-macro globulin (spot 4: 201.6 kDa), 3 forms of fibrinogen gamma (spots 5–7: 54.8 kDa, 54.1 kDa and 51.7 kDa, respectively), serotransferrin (spot 8: 54.9 kDa), 2 forms of human complement component C3b (spot 9: 125.4 kDa and spot 10: 80.0 kDa), pigment epithelium-derived factor (spot 11: 51.0 kDa), insulin-like growth factor binding protein (spot 12: 89.3 kDa), and 3 forms of immunoglobulin M (lgM) heavy chain (spots 13–15: 83.7 kDa, 83.0 kDa and 82.2 kDa, respectively).

Figure 2 presents a heat map which shows a comparative visualization of the individual levels of the differentially expressed protein spots in the control samples (H1–H3), the cancer-suspected samples (S1 and S2) and the bladder cancer patients’ plasma samples (C1–C4). The observed trends of the up- and downregulation of protein abundances in the cancerous and cancer-suspected samples analyzed in respect to those in the samples of healthy individuals are shown in Tables 1 and 2.

The protein spots identified as transferrin (54.9 kDa), fibrinogen gamma (51.7 kDa) and complement C3b (125.4 kDa) occurred abundantly in both groups C and S, but were absent in the normal plasma samples. The remaining identified proteins, apart from a low relative abundance of IgM, showed a high abundance in groups C and S compared with group H.

The ratio values, which compare the relative abundance of the respective proteins between groups C and H, S and H, and C and S, are given in Table 2. The highest ratio values of C/H and S/H were found for vitamin D-binding protein (8.29 and 8.25, respectively). This indicates that the relative abundance of vitamin D-binding protein in both groups C and S was more than 8 times higher than that of the normal (H) group. The ratio values of C/H and S/H were 2.0 or higher for 42.9 kDa haptoglobin (4.64 and 5.64,
respectively), 43.1 kDa haptoglobin (2.63 and 3.11, respectively), and alpha-2-macroglobulin (3.11 and 4.00, respectively). The ratio values of C/H and S/H for 54.8 kDa and 54.1 kDa fibrinogen forms (2.09 and 1.53, respectively, and 1.8 and 2.04, respectively) and 80.0 kDa complement C3b (2.25 and 1.6, respectively), and pigment epithelium-derived factor (2.23 and 1.67, respectively) ranged from 1.5 to 2.0.

In contrast, low values of the ratio were found for IgM molecular forms 83.7 kDa (0.25 and 0.12, respectively), 83.0 kDa (0.20 and 0.13, respectively) and 82.2 kDa (0.33 and 0.29, respectively), when groups C and S were compared to group H. Finally, the ratio value was nearly 1 for insulin-like growth factor binding protein when comparing C and H (0.64), and S and H (0.78) groups. On the other hand, similar ratio values were observed when comparing protein abundances in groups C and S.
Table 2. Relative abundance of the potential plasma biomarkers of bladder cancer identified by proteomic analyses

<table>
<thead>
<tr>
<th>Spot No.</th>
<th>Identified protein</th>
<th>Function</th>
<th>Mr [kDa]</th>
<th>Ratio of the relative protein abundance (Table 1) between the groups:</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>haptoglobin</td>
<td>positive acute phase protein, inflammatory response²⁴</td>
<td>43.1</td>
<td>C/H 2.63 S/H 3.11 C/S 0.84</td>
</tr>
<tr>
<td>2</td>
<td>haptoglobin</td>
<td>transport of vitamin D metabolites, immune functions, chemotactic cofactor²³</td>
<td>42.9</td>
<td>C/H 4.64 S/H 5.64 C/S 0.82</td>
</tr>
<tr>
<td>3</td>
<td>vitamin D-binding protein</td>
<td></td>
<td>59.2</td>
<td>C/H 8.29 S/H 8.25 C/S 1.0</td>
</tr>
<tr>
<td>4</td>
<td>alpha-2-macroglobulin</td>
<td>protease inhibitor, binding various cytokines and growth factors²⁸</td>
<td>201.6</td>
<td>C/H 3.11 S/H 4.00 C/S 0.78</td>
</tr>
<tr>
<td>5</td>
<td>fibrinogen gamma</td>
<td></td>
<td>54.8</td>
<td>C/H 2.09 S/H 1.53 C/S 1.36</td>
</tr>
<tr>
<td>6</td>
<td>fibrinogen gamma</td>
<td></td>
<td>54.1</td>
<td>C/H 1.8 S/H 2.04 C/S 0.88</td>
</tr>
<tr>
<td>7</td>
<td>fibrinogen gamma</td>
<td></td>
<td>51.7</td>
<td>C/H 2,274.0* S/H 1,510.3* C/S 1.51</td>
</tr>
<tr>
<td>8</td>
<td>transferrin</td>
<td>iron homeostasis, erythropoiesis, innate immune system, negative acute phase protein²⁶</td>
<td>54.9</td>
<td>C/H 1,626.1* S/H 1,617.6* C/S 1.01</td>
</tr>
<tr>
<td>9</td>
<td>complement C3b</td>
<td>complement pathway activation and regulation²⁹</td>
<td>125.4</td>
<td>C/H 645.7* S/H 980.2* C/S 0.66</td>
</tr>
<tr>
<td>10</td>
<td>complement C3b</td>
<td></td>
<td>80.0</td>
<td>C/H 2.25 S/H 1.6 C/S 1.4</td>
</tr>
<tr>
<td>11</td>
<td>pigment epithelium-derived factor</td>
<td>multifunctional factor with neurotrophic, anti-oxidative, anti-inflammatory, and anti-angiogenic properties (skin homeostasis and wound healing)³⁰</td>
<td>51.0</td>
<td>C/H 2.23 S/H 1.67 C/S 1.33</td>
</tr>
<tr>
<td>12</td>
<td>insulin-like growth factor binding protein</td>
<td>regulation of cell growth and survival³¹</td>
<td>89.3</td>
<td>C/H 0.64 S/H 0.78 C/S 0.82</td>
</tr>
<tr>
<td>13</td>
<td>IgM</td>
<td></td>
<td>83.7</td>
<td>C/H 0.25 S/H 0.12 C/S 2.13</td>
</tr>
<tr>
<td>14</td>
<td>IgM</td>
<td>primary immune response to antigens³²</td>
<td>83.0</td>
<td>C/H 0.20 S/H 0.13 C/S 1.61</td>
</tr>
<tr>
<td>15</td>
<td>IgM</td>
<td></td>
<td>82.2</td>
<td>C/H 0.33 S/H 0.29 C/S 1.12</td>
</tr>
</tbody>
</table>

C – patients with bladder tumors; H – healthy controls; IgM – immunoglobulin M; Mr – molecular mass; S – patients suspected of having cancer; * because the spot was not detected in the normal plasma sample, the given value corresponds to the value of the mean relative abundance (see Table 1).

Discussion

The proteomic analyses of plasma samples of the patients with urothelial bladder cancer and cystitis allowed us to visualize 15 differentially expressed protein spots, which were identified as 9 proteins (Fig. 1, 2 and Tables 1, 2). The identified proteins showed some discrepancies between the calculated molecular masses (Mr) (Table 1) and the theoretical SwissProt/NCBI database matches. Such differences, also reported for some urine and plasma bladder cancer proteins, might be related to post-translational modifications (glycosylation and phosphorylation) and may have resulted from pathological tissue conditions (glycosylation, proteolytic cleavage or association with other molecules), possibly influencing the size, properties and electrophoretic mobility of the affected molecule(s)¹⁸,²²,³³–³⁵

Our results showed some changes between the 2 cancer groups in relation to the normal group, but none between group C patients with active urothelial carcinoma and group S patients with acute cystitis. However, the patients from group S had undergone a transurethral resection of a urothelial bladder tumor 2 years earlier, so they might have recurrent malignancy, still unidentified. On the other hand, the synthesis of the identified proteins is associated with the inflammatory state that is always present in cancer and of course in cystitis.

The protein identification of the 2DE pattern of spots (Fig. 1 and Table 1) revealed the presence of 2 molecular forms of haptoglobin (β chain: 43.1 kDa and 42.9 kDa), 3 of IgM (heavy chain: 83.7 kDa, 83.0 kDa, 82.2 kDa), and moreover, 1 of a low molecular mass form of transferrin (54.9 kDa), which were absent in the normal plasma. They probably represent several glycovariants of these glycoproteins. The relative abundance of haptoglobin, transferrin and IgM molecular forms in bladder cancer patients’ plasma samples showed significant differences compared to those of the normal group (Table 2). Such differences might be associated with some defects in glycan structures of glycoproteins, which in malignancy may take a variety of forms, such as hypo- and hyper-glycosylated forms, leading to the occurrence of glycoforms with incomplete truncated oligosaccharide parts, heavily sialylated, fucosylated or branched structures, and even to the loss of expression or the appearance of novel structures.³⁴ On the other hand, the presence of several spots of fibrinogen gamma (54.8 kDa, 54.1 kDa and 51.7 kDa) with evidently lower molecular masses than the untouched native form might reflect the presence of proteolytic degradation products rather than the occurrence of carbohydrate-deficient variants.

The proteomic analyses of bladder cancer plasma samples (Table 1) allowed us to distinguish 3 groups of plasma proteins, whose presence might be of value as...
potential bladder cancer markers. The 1st one comprised the isoforms of proteins absent in the normal group, but occurring abundantly in the plasma of the cancer group (Table 1). They were 54.9 kDa plasma transferrin, 51.7 kDa fibrinogen gamma and 125.4 kDa complement C3b. The 2nd group consisted of glycoproteins released into circulation in high concentrations during immunoinflammatory processes. They are well-known members of the acute phase glycoprotein group, such as haptoglobin and alpha-2-macroglobulin, as well as 2 multifunctional glycoproteins, vitamin D-binding protein and pigment epithelium-derived factor (51.0 kDa). The 3rd group of potential bladder cancer markers comprised 3 molecular forms of IgM (heavy chain of IgM: 83.7 kDa, 83.0 kDa, 82.2 kDa), which may be involved in tumor immunity and biological changes in the tumors.37

Interestingly, our results show that vitamin D-binding protein is evidently associated with bladder cancer. Its relative abundance in patients’ plasma samples was 8 times higher than in the normal plasma samples (Table 2). That multifunctional glycoprotein, besides its role in transporting vitamin D and circulating metabolites, is involved in the elimination of dead or injured cells, macrophage activation and neutrophil chemotaxis under inflammatory conditions.25,38 However, its involvement in the carcinogenesis of bladder cancer is controversial and requires further analysis.39

Among the selected differentially expressed glycoproteins, there are prognostic and predictive markers associated with several other cancers. An elevated concentration of transferrin has been described in the urine of bladder cancer patients.28 It not only takes part in normal iron metabolism, but is also involved in iron transport to highly proliferative cancer tissues, requiring high amounts of iron ions as a co-factor for ribonucleotide reductase enzyme for DNA synthesis.28 An elevated fibrinogen concentration in the plasma of bladder cancer patients has been described as an independent indicator of the late stage of the disease.27 The low abundance of IgM observed by us might reflect the disturbances in maintaining immunocompetence in specific recognition and elimination of pre-cancerous, cancerous and age-related lesions in tissues.32 Simultaneously, in contrast to the decrease of the IgM level, the high abundance of complement C3b reflects the activation of innate immunity. To recapitulate, the parameters described by us are mostly related to bladder cancer-linked inflammatory responses, which are known to play decisive roles at different stages of tumor development.40

Conclusions

The results of proteomic analyses of the plasma samples of patients with urothelial bladder cancer allowed us to select 9 differentially expressed glycoproteins as potential bladder cancer markers. We recommend vitamin D-binding protein, haptoglobin, transferrin, fibrinogen, IgM, complement C3b, alpha-2-macroglobulin, and pigment epithelium-derived factor as a group of markers associated with bladder cancer. They might be considered crucial parameters for the development of tests useful in clinical practice. However, in our opinion, the evaluation of haptoglobin, transferrin and IgM glycovariants, or various cleavage products of fibrinogen and complement C3b might be more promising and more sensitive and specific than the evaluation of their total respective protein concentrations for bladder cancer diagnosis and disease progression monitoring.

Considering the complexity of the proteomic technique we used and the future usefulness of the test in clinical practice, the results should be confirmed by less expensive and time-consuming methods in a larger group of patients.

References


